Know Cancer

or
forgot password

A Phase I Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation


Phase 1
N/A
N/A
Open (Enrolling)
Both
Leukemia, Myelodysplastic Syndrome

Thank you

Trial Information

A Phase I Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation


Inclusion Criteria:



- Prior to receiving treatment, some patients may undergo diagnostic and/or other
testing of their WT1 malignancies to determine if their disease is likely to respond
to treatment with WT1 specific T cells. Alternatively, blood samples may be required
for research tests to ascertain that the WT1-specific T-cells do not contain any
cells that could react against the patient. These patients will sign a separate
pre-treatment consent. If it is determined that a patient will qualify for and might
benefit from infusions of WT1 CTLs, he/she will go on to sign the standard treatment
consent for MSKCC IRB # 07-055 and be enrolled and treated on trial, if all other
eligibility criteria are met.

- Patients eligible for this trial will include patients with a pathologically
confirmed diagnosis of leukemia or myelodysplastic syndrome (MDS) who, following an
allogeneic hematopoietic cell transplant, have relapsed with leukemia as demonstrated
morphologically on peripheral blood smear or bone marrow aspirate, or have recurrent
persistent minimal residual disease as demonstrated by at least 2 sequential testings
separated by at least 1 week demonstrating molecular evidence of residual leukemia or
MDS by FISH or cytogenetics. In addition, patients who are to receive an allogeneic
hematopoietic cell transplant as treatment for a leukemia or myelodysplastic syndrome
that has an expected of risk of relapse post transplant of >30% will be eligible to
have donor-derived WT1 peptide specific T cells generated prior to or at the time of
transplant for immediate use post transplant at such time that the patient is found
to have minimal residual disease or relapse. This includes patients with AML or ALL
that is either refractory to primary induction therapy or is at any stage later than
first relapse for AML or ALL, CML in a secondary chronic phase, accelerated disease
or after treatment for blast crisis or RAEB or RAEBT stages of MDS which have not
responded to or recurred following induction therapy. Furthermore, the patient's
leukemic or MDS blasts should be documented to express the WT1 protein detectable by
immunohistopathologic analysis of diagnostic paraffin embedded marrow biopsies,
obtained at diagnosis of relapse or be of a type known to commonly express WT1 at
high frequency. Expression of WT1 will be assessed by a modification of the technique
of Dupont and Soslow (36) and graded according to an adaptation of the German
Immunoreactive Score (IRS) which is the product of subscores for intensity of
immunoreactivity (0-3+) and distribution of immunoreactivity (0-4+). For this study,
leukemic blasts with IRS scores of 4-12 will be considered positive.

- A pathologically confirmed diagnosis of leukemia or MDS.

- Patients who have already received an allogeneic hematopoietic cell transplant and
have either a documented relapse of leukemia or MDS or have recurrent persistent
minimal residual disease as documented by at least 2 sequential testings, separated
by 1 week, demonstrating molecular evidence of leukemia or MDS by FISH, cytogenetics
or fluorescent immunocytometry.

- Patients who are to receive an allogeneic hematopoietic cell transplant as treatment
for a leukemia or myelodysplastic syndrome that has an expected risk of relapse
exceeding 30% will be eligible to have donor-derived WT1 peptide sensitized T cells
generated prior to or at the time of transplant for immediate use post transplant at
such time that the patient is found to have minimal residual disease or relapse. This
includes patients with:

- ALL, AML or MDS refractory to primary induction therapy

- ALL or AML at any stage later than 1° relapse

- CML in 2° or greater chronic phase after chemotherapy

- CML in persistent accelerated phase or blast crisis

- High risk MDS (RAEB and RAEB+) which has failed to respond or has recurred following
induction chemotherapy

- The patients' leukemia or MDS blasts must express the WT1 protein detectable by
immunohistopathologic analysis, or; if an adequate sample is not available for
testing, , must have a form of leukemia (ALL, AMLs other than M5) or MDS (2° MDS,
RAEB, RAEBT) known to over express WT1 in a high proportion of cases (>60%). For
patients who develop a documented relapse of leukemia or MDS following transplant,
marrow aspirates should be evaluated for the proportion of blasts expressing WT1 by
immunohistology or FACS whenever possible.

- The patient's hematopoietic cell transplant donor must consent to a 2 volume
leukapheresis or whole blood donations obtained at one phlebotomy which, will total
approximately 250 ml from which the WT-1 specific T cells to be used for adoptive
transfer will be generated

- KPS or Lansky score > or equal to 40

- Adequate bone marrow, renal and hepatic function at the time of treatment with WT1
specific T cells:

- Absolute neutrophil count (ANC) > or equal to 1000/mm3, with or without G-CSF
support.

This requirement may be waived if the patient has hematologic relapse of disease or if
patient has not yet recovered counts from chemotherapy.

- Platelets > or equal to 20,000/mm3. This requirement may be waived if patient has
hematologic relapse of disease or if patient has not yet recovered counts from
chemotherapy.

- Creatinine < than or equal to 2.0mg/dL

- ALT, AST <3.0 and total bilirubin all < 2.5 x the institutional ULN

- There are no age restrictions to this protocol.

- Patients with relapse also detected in the CNS may be treated on this protocol.
However, if intrathecal chemotherapy is being administered, T cells should not be
administered until at least 24 hours thereafter.

Exclusion Criteria:

- Patients with active (grade 2-4) acute graft vs. host disease (GVHD), chronic GVHD or
an overt autoimmune disease (e.g. hemolytic anemia) requiring high doses of
glucocorticosteroid (>0.5 mg/kg/day prednisone or its equivalent) as treatment.

- Patients with other conditions not related to leukemic relapse (e.g. veno-occlusive
disease or uncontrolled bacterial, viral or invasive fungal infection) which are also
life-threatening and which would preclude evaluation of the effects of a T cell
infusion.

- Patients who are pregnant.

Donor Eligibility for Donation of Blood Lymphocytes for Generation of Donor-Derived
WT-1-Specific T Cells.

The eligibility criteria for the donor of blood to be used to generate WT1 peptide
sensitized T cells are:

- The donor of WT-1 specific T. lymphocytes will be the same donor who provided the
patient's hematopoietic stem cell transplant (HSCT). These normal donors will be
evaluated for evidence of prior sensitization to EBV by EBV serology. If the donor is
seropositive, and donor T cells are sensitized with the donor's WT-1 peptide- loaded
EBV transformed B cells, EBV-specific T-cells will also be generated from
seropositive donors generating WT-1 specific T-cells, and their growth and
persistence post transfer will be compared to that of the WT 1 specific T-cells.

- Since the donor will have already undergone an extensive evaluation of his/her health
to ascertain eligibility for donating the patient's HSCT, re-evaluation for this
blood donation will be limited to a clinical history, physical examination and blood
tests to insure against any new condition which, in the opinion of the donor's
physician, preclude the donor from donating the blood required.

- New health conditions which would exclude a transplant donor from a second blood
donation are limited, but include:

- New onset of an HIV infection

- Other uncontrolled infection which could be transmitted to the patient by blood cells
and would place the patient at significant increased risk of severe morbidity or
death.

- Significant anemia with Hgb < than or equal to 10 gm/dl, persisting since the time of
the original transplant donation.

- History of myocardial infarction or stroke since the time of HSCT donation which
might increase the risk of blood donation. A perspective donor will be informed of
the purposes of this study, and its requirements. If he/she consents, the donor will
be requested to provide two blood samplings.

- An initial donation of 25ml blood anticoagulated with heparin or ACD. This blood is
used to establish a B cell line transfused transformed with the B95.8 laboratory
strains of EBV. This EBV+ B cell line/ (EBVBLCL) will be used as an
antigen-presenting cell. When loaded with the pool of WT-1 pentadecapeptides, the
EBVBLCL efficiently sensitize T cells from the same donors against WT-1 as well as
EBV.

Because the establishment and testing of an EBV transformed B cell line suitable for use
as an antigen-presenting cell require 4-5 weeks of in vitro culture, it is important that
this sample be obtained as early as possible for patients at risk for leukemic relapse,
since disease relapse most frequently occurs 2-6 months post transplant. Accordingly, this
blood sample should be obtained from the donor prior to donation of the hematopoietic
progenitor cell transplant whenever possible.

- A donation of either a single standard 2 blood volume leukapheresis collected in
standard ACD anticoagulant. If it is impossible to collect a leukapheresis from some
of the donors, a unit of whole blood will be accepted by the AICTF (Adoptive Immune
Cell Therapy Facility manufacturing the clinical grade cell products under GMP
conditions in MSKCC) for the generation of limited number of T cells. This blood is
required for isolation of the T cells to be sensitized with the pool of WT-1 15-mers
loaded on autologous dendritic cells or autologous EBVBLCL, and propagated in vitro.
In addition, it is required to provide autologous feeder cells essential to sustain
T-cell growth without the risk of stimulating the growth of alloreactive T-cells
capable of inducing GVHD.

- This donation of a leukapheresis or a unit of blood will be obtained from unrelated
HSCT donors at least 2 weeks after their donation of an HSCT, but soon thereafter as
possible.

In addition to providing written consent to these donations of blood for the purpose of
generating WT-1-specific T-cells for potential use in the treatment of recurrent leukemia
or persistent residual disease developing in the patient for whom the donor has provided
an HSCT, each donor will be informed of and asked to provide separate consent to each of
the following potential applications of the blood cells donated:

- The use of a fraction of the cells isolated to generate immune T-cells specific for
viruses, such as Epstein-Barr virus (EBV) and cytomegalovirus (CMV) ,that can cause
lethal infections or lymphomas in transplant recipients. Such T-cells could then be
used, under separate protocols, to treat EBV-associated diseases (IRB 95-024) and/or
to treat CMV infections (IRB 05-065) in the patient receiving the donor's
hematopoietic progenitor cell transplant.

Consenting to this application will limit the number of blood donations that would be
required of any donor, since the white cells donated in a leukapheresis should provide
enough cells to grow immune T-cells against WT-1, EBV and CMV.

The donation of immune T-cells specific for EBV or CMV generated from the donor that are
not used for or required by the patient for whom they were originally intended to a bank
of immune cells that will be started and maintained cryopreserved under GMP conditions in
the Adoptive Immune Cell Therapy Facility at MSKCC, for potential use in the treatment of
other patients with EBV lymphomas or cytomegalovirus infections that express HLA alleles
shared by the donor.

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

assess toxicity of in vitro expanded allogeneic WT1 peptide-specific T-cells derived from transplant donor,when given to patients with leukemia or other WT1+ hematologic malignancy having relapsed after transplant or persistent minimal residual disease

Outcome Time Frame:

conclusion of the study

Safety Issue:

Yes

Principal Investigator

Richard O'Reilly, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center

Authority:

United States: Food and Drug Administration

Study ID:

07-055

NCT ID:

NCT00620633

Start Date:

February 2008

Completion Date:

February 2014

Related Keywords:

  • Leukemia
  • Myelodysplastic Syndrome
  • Bone Marrow
  • Leukemia
  • Myelodysplastic Syndromes
  • Preleukemia

Name

Location

Memorial Sloan Kettering Cancer CenterNew York, New York  10021